(Credits: Giphy)

Lately, Synergy Pharmaceuticals ($SGYP), the biopharmaceuticals company, has been quite popular. Buckle up because earnings reports are right around the corner, but here are a few things to ponder on even after the earnings report come out.

Price Target Summary report: Synergy Pharmaceutical Inc (NASDAQ:SGYP) (Release: 06/05/2016):
The predicted stock prices are all over the place, some predict as high as $19, others as low as $4, as stated by the News Oracle. It is currently trading in a range of $2.81 – $3.29, with their volume of trade being significantly larger than the daily average. It closed at a value of $2.82 but it went up to $2.94 in after hours.

Synergy Pharma Seen “Weighing” Options, Sell-Side Forecasts Upside Regardless of M&A Rumors (Release: 05/05/2016):
It has been rumored that Synergy Pharma might be on the verge of a buy out even though management, says they are “weighing their options and considering marketing opportunities.” As of now, they are only rumors…However, staff writer at Benzinga (@Benzinga) argues that M&A or no M&A, the company is on a good track.

Synergy Pharmaceuticals (SGYP) Stock: Big Gains Coming Soon (Release: 05/05/2016):
Joshua Rodriguez (@CNAFinance), founder of CNAFinance, lists a few of the reasons for the commotion around the stock. One of the main reasons is their plencanatide development for chronic idiopathic constipation, now filed for FDA approbation. The author also emphasizes the fact that if an acquisition does happen, the stock price will soar. Will the earnings reflect their leverage?

But wait, that is not all…

Synergy Pharmaceuticals (NASDAQ:SGYP) & Intrexon Corp (NYSE:XON) Healthcare Stock Intraday Alert (Release: 06/05/2016):
The company has agreed to sell 9,948,337 shares of common stock to institutional investors at $3 per share. The net proceeds will be about $89.7 million, of which will be directed towards commercialization and further clinical development of plecanatide.